AstraZeneca said on Thursday its asthma drug, Tezspire, developed with Amgen, met its main and secondary goals in a late-stage trial for treating eosinophilic oesophagitis, a chronic inflammatory disorder of the oesophagus.
The study showed Tezspire, when compared with a placebo, managed to significantly reduce inflammation in the oesophagus and also ease the frequency and difficulty in swallowing for patients.
The drug belongs to a class of targeted treatments known as monoclonal antibodies. It works by blocking a protein called TSLP, which can trigger inflammation linked to eosinophilic conditions as well as severe asthma.
Tezspire is already approved as a single-use pre-filled syringe in the US, EU and other countries as an add-on treatment for severe asthma.
Reuters
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.